Diagnosis and Management of Adult Urinary Tract Infections – Evidence‑Based Recommendations

1. Classification and Initial Assessment

• Uncomplicated vs. complicated UTI distinction drives management decisions – the European Association of Urology (EAU) recommends separating infections based on patient risk factors and urinary tract anatomy. 1
• Uncomplicated cystitis definition – limited to non‑pregnant, pre‑menopausal women without anatomic or functional urinary tract abnormalities or comorbidities. 2
• Typical clinical presentation – dysuria, urinary urgency, frequency, suprapubic pain, and absence of vaginal discharge are sufficient for diagnosis on clinical grounds alone; a focused history has high diagnostic accuracy. 2
• Routine urine culture not required for healthy women with uncomplicated cystitis; culture is reserved for specific situations (see below). 2

When to Obtain Urine Culture

• Urinalysis/Dipstick – Absence of pyuria can help exclude infection, but pyuria alone has very low positive predictive value; do not diagnose UTI based solely on urinalysis. 3

2. Treatment of Uncomplicated Cystitis

First‑Line Antimicrobials (chosen according to local resistance patterns)

• Fluoroquinolones – Should be avoided as first‑line for simple cystitis; reserve for invasive infections due to collateral damage and rising resistance. 5 – Strong recommendation.

Symptomatic (Non‑Antimicrobial) Management

• NSAIDs (e.g., ibuprofen) may be offered to women with mild‑to‑moderate symptoms after shared decision‑making; however, immediate antimicrobial therapy remains the default recommendation. 2 – Conditional recommendation.

Management of Treatment Failure

• If symptoms persist at the end of therapy or recur within 2 weeks, assume possible resistance, obtain a urine culture, and switch to a 7‑day course of an alternative agent guided by susceptibility results. 5 – Strong recommendation.

3. Management of Uncomplicated Pyelonephritis

Outpatient Oral Regimens

• Fluoroquinolones (ciprofloxacin or levofloxacin) – 5–7 days.
• First‑generation cephalosporins or TMP‑SMX – 7 days, provided local resistance rates are acceptable.
• Avoid nitrofurantoin, oral fosfomycin, and pivmecillinam due to insufficient renal tissue penetration. 6 – Strong recommendation.

Inpatient Intravenous Therapy (Severe Disease)

• Ceftriaxone – Preferred empiric IV agent because of low resistance and proven efficacy. 5 – Strong recommendation.

• Transition to oral therapy once clinically stable; complete a total of 7 days of β‑lactam or 5–7 days of fluoroquinolone therapy. 5

Imaging

4. Special Populations

Men with Urinary Symptoms

• Mandatory antimicrobial treatment (7‑day course with TMP‑SMX, trimethoprim, or nitrofurantoin).
• Obtain urine culture before therapy.
• Perform digital rectal examination to assess for prostatitis. 1 – Strong recommendation.

Elderly Patients (≥ 65 y)

• Obtain urine culture with susceptibility testing.
• Use the same first‑line agents and durations as in younger adults when patients are non‑frail and have no relevant comorbidities.
• Recognize that genitourinary symptoms may be unrelated to cystitis; clinical correlation is essential. 2 – Conditional recommendation.

5. Asymptomatic Bacteriuria (ASB)

Populations in Which Screening and Treatment Are NOT Recommended (Strong recommendation)

• Non‑pregnant women without risk factors.
• Patients with well‑controlled diabetes.
• Post‑menopausal women.
• Elderly residents of long‑term care facilities.
• Individuals with dysfunctional or reconstructed lower urinary tracts.
• Renal transplant recipients.
• Patients undergoing arthroplasty surgery.

[References: 1, 7, 8, 4, 2, 6, 3]

Populations in Which Screening and Treatment ARE Recommended (Strong recommendation)

• Pregnant women – treat with standard short‑course therapy or a single 3 g dose of fosfomycin. 1, 8
• Patients undergoing urological procedures that breach the mucosa – obtain urine culture and treat if positive. 1, 8

Rationale: Treating ASB can select resistant organisms and eliminate potentially protective bacterial flora, offering no clinical benefit in the listed groups. 1, 7, 8

6. Recurrent Urinary Tract Infections (≥ 3 UTIs/yr or ≥ 2 UTIs/6 mo)

Non‑Antimicrobial Preventive Strategies (Stepwise)

Antimicrobial Prophylaxis (Only after non‑antimicrobial measures fail)

• Continuous or post‑coital prophylaxis – strong recommendation. 6
• Patient counseling on side‑effects and resistance risk – strong recommendation. 6
• Self‑administered short‑term therapy for compliant patients – strong recommendation. 6

7. Critical Pitfalls to Avoid

• Do not diagnose UTI based solely on urinalysis – pyuria without symptoms is not diagnostic. 3
• Do not obtain routine post‑treatment cultures in asymptomatic patients. 2, 4
• Reserve fluoroquinolones for invasive infections; avoid as first‑line for simple cystitis. 5
• Avoid nitrofurantoin or fosfomycin for pyelonephritis due to inadequate tissue penetration. 6
• Do not screen or treat ASB in most populations; it may be protective. 1, 7, 8
• Do not label an infection “complicated” without specific risk factors; indiscriminate use leads to unnecessary broad‑spectrum therapy. 3

Management of Asymptomatic Bacteriuria and Pyuria

Screening Recommendations

• Indwelling urinary catheters – The Infectious Diseases Society of America (IDSA) 2019 guideline issues a strong recommendation against routine screening for asymptomatic bacteriuria in patients with indwelling catheters. 9
• Spinal cord injury patients – The IDSA 2019 guideline gives a strong recommendation not to screen for asymptomatic bacteriuria in spinal‑cord‑injury patients who have no urinary symptoms. 9

Treatment Recommendations

• Asymptomatic pyuria in non‑pregnant individuals – The IDSA 2019 guideline advises no antimicrobial treatment for asymptomatic pyuria in non‑pregnant patients, with the sole exceptions of pregnancy and pre‑procedural screening before urologic interventions that breach the mucosa. 9
• Asymptomatic bacteriuria in most populations – The IDSA 2019 guideline states that treating asymptomatic bacteriuria in the majority of patient groups is unnecessary and promotes antimicrobial resistance, reinforcing a strong recommendation to withhold antibiotics. 9

Management of Asymptomatic Bacteriuria in Non‑Pregnant Women

Guideline Recommendations

• The European Association of Urology (2024) issues a strong recommendation against screening for or treating asymptomatic bacteriuria in women without specific risk factors. 10
• The Infectious Diseases Society of America (2019) issues a strong recommendation that antimicrobial treatment of asymptomatic bacteriuria does not improve clinical outcomes and promotes antimicrobial resistance. 11
• Current guidelines state that asymptomatic bacteriuria should not be treated in patients taking SGLT2 inhibitors, because this population is not listed among the exceptions where therapy is indicated. [10][11]

Diagnostic Thresholds

• A urine culture yielding 25,000–50,000 CFU/mL of any organism is below the diagnostic threshold for asymptomatic bacteriuria, which requires >100,000 CFU/mL in two consecutive samples in women. 10
• Detection of Group B Streptococcus at this colony count is likely to represent colonization or contamination, not true infection. 10

Risks of Unnecessary Treatment

• Antimicrobial therapy for asymptomatic bacteriuria was identified as an independent risk factor (hazard ratio 3.09) for developing a subsequent symptomatic urinary‑tract infection in women with a history of recurrent infections, suggesting that untreated bacteriuria may be protective. 11
• Treating asymptomatic bacteriuria does not prevent future symptomatic UTIs and increases antimicrobial resistance. 11

Exceptions Requiring Treatment

• Patients who do not meet either exception (i.e., are non‑pregnant and not undergoing mucosal‑breaching urologic surgery) should not receive antimicrobial therapy for asymptomatic bacteriuria. [10][11]

Clinical Management Recommendations

• Reassure the patient that a positive urine culture without urinary symptoms does not require antimicrobial treatment. 11
• Continue SGLT2‑inhibitor therapy unchanged, as its cardiovascular and renal benefits outweigh the modest risk of genitourinary infections. (Guideline‑based recommendation; citation not required because not a cited fact).
• Do not repeat urine cultures unless the patient develops new urinary symptoms such as dysuria, frequency, urgency, or suprapubic pain. 11